Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

11.33 +2.39 (+26.73%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Keep an eye on the top gainers and losers in Monday's session. ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Friday? ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
Analyst Ratings for Day One Biopharmaceutical ↗
 
Via Benzinga
News headline image
Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’ ↗
Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement. 
Via Stocktwits
News headline image
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout ↗
Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio. 
Via Benzinga
News headline image
Mersana Catapults 200% On Day One Bio's Surprise Buyout ↗
Shares of Mersana Therapeutics catapulted early Thursday after Day One Biopharmaceuticals agreed to buy it. 
Via Investor's Business Daily
News headline image
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal ↗
The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday. 
Via Stocktwits
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Day One (DAWN) Q2 Revenue Jumps 313% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) Reports Q2 2025 Earnings: Revenue Growth but Wider-Than-Expected Loss ↗
Day One Biopharmaceuticals reports Q2 2025 earnings with revenue growth but wider-than-expected loss, causing an 11.8% stock drop. OJEMDA sales rise 10% QoQ, while pipeline advances. 
Via Chartmill
News headline image
Biotech Investing: How PRVs Can Unlock Major Opportunities
Biotech Investing: How PRVs Can Unlock Major Opportunities 
Via News Direct
News headline image
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally ↗
Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%. 
Via InvestorPlace
Topics Economy
News headline image
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024 ↗
DAWN stock results show that Day One Biopharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal ↗
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting... 
Via Talk Markets
News headline image
DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024 ↗
DAWN stock results show that Day One Biopharmaceutical missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Dow Up Over 340 Points As Stocks Snap Back ↗
The Dow Jones Industrial Average is building on this morning's gains, up 343 points at last look, while the S&P 500 and Nasdaq Composite sit firmly in the black as well. 
Via Talk Markets
Topics Stocks
News headline image
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.